TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01525524

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: In active stimulation(active Transcranial Direct Current Stimulation), the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp (which is located on the intersection of the sagittal and median curves). The device will deliver a charge of 2mA for 30 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: In active stimulation(active Transcranial Direct Current Stimulation), the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp (which is located on the intersection of the sagittal and median curves). The device will deliver a charge of 2mA for 30 minutes.
Study: NCT03924427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Oral tablet administration
Study: NCT02688725

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: post mastectomy ultrasound
Description: post mastectomy ultrasound
Study: NCT03394118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: A cycle of study treatment is defined as 28 days. Each subject will continue the study drug(Osimertinib) until disease progression or manifestation of unacceptable toxicity during the study period. The study drug will be administered orally as one 80 mg tablet once a day. The initial dose of the study drug 80 mg daily can be reduced to 40 mg once daily.
Study: NCT01942304

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Calcium phosphosilicate alloplastic bone putty in direct sinus augmentation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anorganic bovine bone mineral in direct sinus augmentation
Study: NCT00493714

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Surveys lasting 30 minutes or more.

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Surveys lasting 30 minutes or more.
Study: NCT02287805

Intervention type: OTHER
Intervention: qualitative survey

Intervention type: OTHER
Intervention: quantitative survey

Intervention type: OTHER
Intervention: quantitative survey
Study: NCT06004193

Intervention type: BEHAVIORAL
Intervention: Exercise
Description: At least 150 minutes of exercise in a week
Study: NCT04440462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sugar and water solution
Description: 2 ml of a water and sugar solution (3 full-teaspoons of granulated sugar dissolved in half glass of water)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sterile water
Description: 2 ml of sterile water
Study: NCT05247060

Intervention type: OTHER
Intervention: no experimental intervention
Description: There will not be any experimental intervention. The study will be conducted according with normal clinical practice
Study: NCT01962467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/LEV FDC
Description: Intranasal aqueous microsuspension containing 25.0 microgram (µg) of FF and 50 µg of LEV as a fixed dose combination. It will be administered as two 50 µL sprays per nostril in the morning in a fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF
Description: Intranasal aqueous microsuspension containing 27.5µg of FF. It will be administered as two 50 µL sprays per nostril in the morning in a fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEV
Description: Intranasal aqueous microsuspension containing 50 µg of LEV. It will be administered as two 50 µL sprays per nostril in the morning in a fasted state
Study: NCT03923504

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Intervention (PAI)
Description: Those who opt-in to attend in-person study visits and to undergo COVID testing will also complete an MRI exam and CPET testing. Participants unwilling to have COVID testing done will only complete an MRI exam and home-based testing. All testing will take place either within 6 weeks of initiating systemic treatments or within 8 weeks of completing radiation then at 3 \& 6 months. Patients may participate in 1-2 training sessions per week offered under the direct supervision of a master's level clinical exercise physiologist, as well as 1-2 sessions at home. PAI sessions consist of slow aerobic warm-up, followed by 20 minutes of strength training,15 minutes of progressive intensity aerobic exercise (AE), and then 10 minutes of stretching for cool-down. Participants will have the ability to participate in training sessions facilitated via online channels at home.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living Control
Description: Patients randomized to the control arm will either attend online sessions via secure video conferencing (e.g. Zoom) or telephone or to come to a centralized meeting location (if safety allows) to participate in organized health workshops. Session attendance will be required 2 times/month (over the 6 months). Make up sessions will be offered for those participants who have to miss a group session. Each session lasts 60 minutes and matches the number of visits made by the PAI group as much as possible.
Study: NCT03660280

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Specific probiotic lactobacilli (added to stabilized ongoing treatment)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03812783

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hepatic arterial infusion chemotherapy
Description: administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folfox Protocol
Description: Oxaliplatin , fluorouracil, and leucovorin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: administration of Sorafenib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: administration of Sorafenib

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion chemotherapy
Description: administration of Irinotecan, Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: Irinotecan, Oxaliplatin , fluorouracil, and leucovorin
Study: NCT03018821

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard - Yinchengao Decoction plus Ganlu Detoxification Pill
Description: Yinchengao Decoction plus Ganlu Detoxification Pill is one Chinese Medicine Formula for the TCM syndrome: Damp-heat blocking middle jiao.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir or Tenofovir
Description: Western drug for anti-HBV such as Entecavir and Tenofovir
Study: NCT02384785

Intervention type: DEVICE
Intervention: Transcutaneous Electric Nerve Stimulation
Description: Electric currents: 'Transcutaneous Electric Nerve Stimulation' and Transcranial Direct Current Stimulation will be applied on the back of the patients in parallel to the implanted electrodes. Implanted electrode will measure voltages that generated near the spinal cord tissue.
Study: NCT04064944

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: blood purification equipment
Description: The subjects enrolled in this study will undergo blood purification treatment, and will be randomized into either immunoadsorption group or plasma exchange group, and the following indicators will be evaluated: (1) changes in EDSS scores and visual acuity before and after treatment; (2) changes in AQP4-IgG levels; (3) the safety of immunoadsorption treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: blood purification equipment
Description: The subjects enrolled in this study will undergo blood purification treatment, and will be randomized into either immunoadsorption group or plasma exchange group, and the following indicators will be evaluated: (1) changes in EDSS scores and visual acuity before and after treatment; (2) changes in AQP4-IgG levels; (3) the safety of immunoadsorption treatment.
Study: NCT04629365

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: KD group consumed less than 50g/day of carbohydrates

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Diet
Description: ND group consumed 55% of the caloric intake from carbohydrates
Study: NCT03018821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir or Tenofovir
Description: Western drug for anti-HBV such as Entecavir and Tenofovir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir or Tenofovir
Description: Western drug for anti-HBV such as Entecavir and Tenofovir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard - Ge Xia Zhu Yu Decoction
Description: Ge Xia Zhu Yu Decoction is one Chinese Medicine Formula for the TCM syndrome: internal blood stasis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advanced - Supplemented Taohong Huazhuo Decoction
Description: Supplemented Taohong Huazhuo Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Damp-heat blocking middle jiao.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard - Chaihu Shugan San
Description: Chaihu Shugan San is one Chinese Medicine Formula for the TCM syndrome: Liver depression and qi stagnation.
Study: NCT01679340

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1
Description: Mode of administration: orally (capsules) Dosing schedule:80mg/m2, Bid,D1-14,every 3 week,for 8-10cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Mode of administration: orally (capsules) Dosing schedule:80mg/m2, Bid,D1-14,every 3 week,for 8-10cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Mode of administration: intravenously Doseing schedule: 65 mg/m2 D1,D8,every 3 week, for 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Mode of administration: intravenously Dosing schedule: 75mg/m2 D1,every 3 week,for 6 cycle
Study: NCT02021149

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High intensity whole-body infrared heating
Description: The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Weekly psychotherapy using cognitive behavioral therapy sessions with a therapist.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Psychotherapy
Description: Weekly psychotherapy using cognitive behavioral therapy sessions with a therapist.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychotherapy
Description: Weekly psychotherapy using cognitive behavioral therapy sessions with a therapist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Weekly questionnaires to assess changes in mood, perceptions of self and perceptions of effectiveness of the therapist/patient bond will be administered.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Questionnaires
Description: Weekly questionnaires to assess changes in mood, perceptions of self and perceptions of effectiveness of the therapist/patient bond will be administered.

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: Weekly questionnaires to assess changes in mood, perceptions of self and perceptions of effectiveness of the therapist/patient bond will be administered.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Low intensity whole-body infrared heating
Description: Attenuated heating using only heating coils at the bottom of the Heckel device. This results in only a minor increase in skin temperature and no increase in core body temperature. The participant will still feel heat and will see similar lighting and hear similar sounds as those occurring during actual WBH, and will be in the chamber for the same period of time.
Study: NCT00588380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1
Description: GLP-1 infused at 0.75 pmol/kg/min from 121-180 minutes, GLP-1 infused at 1.55 pmol/kg/min from 181-240 minutes,
Study: NCT03748420

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adherence Intervention
Description: The adherence enhanced intervention consists of clinical decision support related to cardiovascular risk factors enhanced with external medication adherence information and is delivered at the point of care to the healthcare provider and patient.
Study: NCT01066650

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endeavor Resolute (Biolinx-based Zotarolimus-eluting stent)
Description: Drug eluting Stent
Study: NCT03018821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advanced - Soothe the liver and regulate qi Decoction
Description: Soothe the liver and regulate qi Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Liver depression and qi stagnation.
Study: NCT01066650

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience V (Everolimus-eluting stent)
Description: Drug eluting stent
Study: NCT00862524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-334543, EGFR/ErbB2 inhibitor; oral
Description: multiple dose, escalating

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, nucleoside analogue; intravenous
Description: multiple dose, single schedule
Study: NCT04422197

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botox
Description: effect of botox injection in abdominal wall muscle post major abdominal surgery in terms of postoperative pain, incidence of incisional hernia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery without botox injection
Description: surgery without botox injection
Study: NCT03045640

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FSI ECD
Description: The FSI ECD intervention was delivered in a structured curriculum format, covering a range of topics from health, water and sanitation, good hygiene, early stimulation, conflict resolution, to good communication. It was designed to improve vulnerable households home environment and engagement with their children in order to improve child development outcomes. The curriculum was delivered by bachelor-level trained staff with beneficiaries on an individual, one on one basis, using active coaching to promote child well being and behaviors with caregivers.
Study: NCT00438490

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant Human Prolactin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Prolactin
Study: NCT03516110

Intervention type: OTHER
Intervention: Data collection
Description: Subjects will be treated in accordance with usual medical practice during their participation in this study. No additional assessments or tests will be required.

Intervention type: OTHER
Intervention: Data collection
Description: Subjects will be treated in accordance with usual medical practice during their participation in this study. No additional assessments or tests will be required.

Intervention type: OTHER
Intervention: Data collection
Description: Subjects will be treated in accordance with usual medical practice during their participation in this study. No additional assessments or tests will be required.
Study: NCT02132858

Intervention type: OTHER
Intervention: cytology specimen collection procedure
Description: Correlative studies

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03679182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine 5 mg Tab at 0, 12, 24, and 36 hours
Study: NCT01206101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Dose escalation of liraglutide up to 1.2 to 1.8 mg before islet cell transplant until the planned number of transplanted subjects is complete or subject is transplanted. After islet cell transplant, subjects continue to receive the reached liraglutide dose for 52 weeks. Injected subcutaneously(under the skin) once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Dose escalation escalation of liraglutide up to 1.2 to 1.8 mg before islet cell transplant until the planned number of transplanted subjects is complete or subject is transplanted. After islet cell transplant, subjects continue to receive the reached liraglutide placebo dose for 52 weeks. Injected subcutaneously (under the skin) once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Dose escalation escalation of liraglutide up to 1.2 to 1.8 mg before islet cell transplant until the planned number of transplanted subjects is complete or subject is transplanted. After islet cell transplant, subjects continue to receive the reached liraglutide placebo dose for 52 weeks. Injected subcutaneously (under the skin) once daily.
Study: NCT03645811

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Music therapy was applied in the application room. Via a portable computer, students listened to the mahur maqam for 20 minutes under the supervision of the investigators using an MP3 player.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EFT
Description: EFT includes taps, nine gamut sequences, and eye movements on the meridian system, focusing on the individual's inhibiting thoughts, disturbing emotions, or memories. EFT regulates the flow of energy in the meridian system of the individual, causing relaxation in the mind, body, and emotions.
Study: NCT02868151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Ascorbic acid oral supplementation 1g four times daily for the entire treatment period and 30 days after treatment by tapering the dose of the drug to half. The drug has to be started 2 days prior to initiation of treatment of cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc acetate
Description: Zinc acetate 50mg tablets orally twice daily for entire period of cancer treatment
Study: NCT03685929

Intervention type: PROCEDURE
Intervention: Punch skin biopsy
Description: Two punch biopsies will be performed in each patient, one at the border of the skin lesion, and one at the adjacent healthy skin. A disposable biopsy punch of 4 mm will be used. A biopsy punch is a small circular blade (like an apple corer) which is rotated into the skin to obtain a cylindrical specimen. Local anaesthesia will be applied and the circular wound will be closed by a single suture. Sutures will be removed after one week.

Intervention type: PROCEDURE
Intervention: Punch skin biopsy
Description: Two punch biopsies will be performed in each patient, one at the border of the skin lesion, and one at the adjacent healthy skin. A disposable biopsy punch of 4 mm will be used. A biopsy punch is a small circular blade (like an apple corer) which is rotated into the skin to obtain a cylindrical specimen. Local anaesthesia will be applied and the circular wound will be closed by a single suture. Sutures will be removed after one week.

Intervention type: PROCEDURE
Intervention: Punch skin biopsy
Description: Two punch biopsies will be performed in each patient, one at the border of the skin lesion, and one at the adjacent healthy skin. A disposable biopsy punch of 4 mm will be used. A biopsy punch is a small circular blade (like an apple corer) which is rotated into the skin to obtain a cylindrical specimen. Local anaesthesia will be applied and the circular wound will be closed by a single suture. Sutures will be removed after one week.
Study: NCT01718366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox, Vitamin D and Azacitidine
Description: association of Deferasirox (group 1: 5-10-15/mg/kg/day according to dose level group), Vitamine D (100000U/week) and Azacitidine (75 mg/kg/day day1-day7)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox, Vitamin D and Azacitidine
Description: association of Deferasirox (group 1: 5-10-15/mg/kg/day according to dose level group), Vitamine D (100000U/week) and Azacitidine (75 mg/kg/day day1-day7)
Study: NCT01739348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verubecestat (Part I and Part II)
Description: Single 12 mg verubecestat tablet once daily, taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verubecestat (Part I and Part II)
Description: Single 40 mg verubecestat tablet once daily, taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verubecestat (Part I and Part II)
Description: Single 60 or 40 mg verubecestat tablet once daily, taken orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part I)
Description: Single placebo tablet matching verubecestat treatment once daily, taken orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Verubecestat (Part II)
Description: Single 40 mg verubecestat tablet once daily, taken orally
Study: NCT02632461

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Podcasts
Description: Participants will receive twice weekly podcasts that will cover topics related to weight loss.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Podcasts
Description: Participants will receive twice weekly podcasts that will cover topics related to weight loss.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Diet Application
Description: Participants will use a mobile application on their smartphone to track their diet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bite Counter
Description: Participants will use a wrist-worn Bite Counter to track the number of bites in their diet per day.
Study: NCT03018821

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard - Xiaoyao powder
Description: Xiaoyao powder is one Chinese Medicine Formula for the TCM syndrome: Stagnation of liver qi and spleen deficiency.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advanced - Supplemented Ganbi Decoction
Description: Supplemented Ganbi Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Stagnation of liver qi and spleen deficiency.